Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) dropped 3% during trading on Thursday . The company traded as low as $13.24 and last traded at $13.31, with a volume of 279,481 shares changing hands. The stock had previously closed at $13.72.

Several equities research analysts recently issued reports on ADMS shares. Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 9th. Noble Financial restated a “buy” rating and issued a $25.00 target price on shares of Adamas Pharmaceuticals in a report on Friday, July 22nd. Needham & Company LLC restated a “buy” rating and issued a $38.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, July 20th. Mizuho restated a “hold” rating and issued a $17.00 target price on shares of Adamas Pharmaceuticals in a report on Wednesday, May 11th. Finally, Credit Suisse Group AG restated a “buy” rating and issued a $21.00 target price on shares of Adamas Pharmaceuticals in a report on Monday, July 25th. Two analysts have rated the stock with a sell rating and nine have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $32.00.

The firm’s market cap is $287.49 million. The firm has a 50-day moving average of $14.51 and a 200-day moving average of $15.29.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP boosted its stake in Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned about 0.38% of Adamas Pharmaceuticals worth $1,966,000 as of its most recent filing with the SEC.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.